CoreBiome is happy to announce it has been awarded a Technology Commercialization Grant to help kick off new initiatives. The $220,000 grant will be used to accelerate commercialization of technologies licensed from the University of Minnesota, including synthetic DNA standards used to ensure sequencing quality, and novel algorithms used in analysis of microbiome data.
Associate Vice President for Research of the University of Minnesota’s Academic Health Center, Tucker LeBien, says “[they] are thrilled to support CoreBiome’s technologies and their potential to accelerate the drug discovery process and impact the lives of patients”. Funding for this grant comes from the Translational Product Development Fund (TPDF) Biomedicine and Bioethics Innovation Grant program.
The full press release can be found here.